Measuring Patient Persistency with Drug Therapy Using Methods for the Design and Analysis of Natural History StudiesByEric S. Johnson, PhD,Essy Mozaffari, PharmD, MPHAugust 1st 2002
An Economic Analysis of Switching to Latanoprost from a Beta-Blocker or adding Brimonidine or Latanoprost to a Beta-Blocker in Open-Angle Glaucoma or Ocular HypertensionByWilliam C. Stewart, MD,Jessica Leech, BS,Elizabeth D. Sharpe, MD,John Kulze, MD,John Ellyn, MD,Douglas G. Day, MDAugust 1st 2002
Population-Based Persistency Rates for Topical Glaucoma Medications Measured with Pharmacy Claims DataBySamaresh Dasgupta, MHS,Vikki Oates, MAS,Brahim K. Bookhart, MBA,Baze Vaziri, MBA, CPA,Gail F. Schwartz, MD,Essy Mozaffari, PharmD, MPHAugust 1st 2002
Rates of Discontinuation and Change of Glaucoma Therapy in a Managed Care SettingByJoshua J. Spooner, PharmD,Michael F. Bullano, PharmD,Laurence I. Ikeda, MD,Tara R. Cockerham, PharmD,William J. Waugh, PharmD,Thomas Johnson, PhaAugust 1st 2002
Dicontinuation Rates of Topical Glaucoma Medications in a Managed Care PopulationByFadia T. Shaya, PhD, MPH,C. Daniel Mullins, PhD,Winston Wong, PharmD,Jeannie Cho, PharmDAugust 1st 2002
Measuring Persistency and Intraocular Pressure-Controlled Days in Patients Receiving Topical Glaucoma MedicationsByGail F. Schwartz, MD,Robert Platt, PhDAugust 1st 2002
